Genmab wins new approval for Darzalex, doubles income guidance
Genmab and Janssen have won what an analyst calls “a surprisingly rapid” approval of a new indication for their blockbuster in the making Darzalex. It triggers a milestone payment for the Danish biotech which now hikes its guidance once again.
BY MARTIN HAVTORN PETERSEN & RITZAU FINANS
The US FDA opted to approve the promising bone marrow cancer treatment Darzalex from Janssen and its biotech partner Genmab in a new indication on Monday.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Genmab CEO about wonder drug: ”It’s incredible”
For abonnenter
Genmab prepares for a slew of clinical studies
For abonnenter
